Sequoya Bio

Sequoya Therapeutics is a biotechnology company focused on discovering and developing a new class of small molecule medicines that target RNA and RNA-binding proteins (RBPs). Founded by pioneers in RNA biology, including Nobel Laureate Phillip Sharp, the company leverages a proprietary platform to identify novel druggable sites on RNA structures and regulatory elements. Their approach aims to address diseases that are currently undruggable by traditional protein-targeting methods, with an initial focus on oncology, neurodegeneration, and rare genetic disorders. The company is currently in the pre-clinical stage, supported by a significant Series A financing round from leading life science investors such as 5AM Ventures and Arch Venture Partners.